Certara Introduces Certara.AI, the Life Sciences Specialized GPT Platform
Certara.AI Improves Drug Research & Development Processes with Secure, Client-Specific, A.I. Applications PRINCETON, N. J.—October…
Certara2023 年 10 月 5 日
Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model
Hugo Geerts, Silke Bergeler, Mike Walker, Piet van der Graaf, Jean-Philippe Courade. Sci Rep. 2023…
Certara2023 年 10 月 5 日
How Modeling Can Help to Improve Children’s Access to Properly Evaluated Medications
Regulatory guidance paves the way to address ethical concerns in pediatric trials, and how additional…
Certara2023 年 10 月 5 日
Clinical Pharmacology Issues That Can Lead to Approvability Problems for Your Drug
临床药理信息占药品说明书的 50% 以上。Inadequate clinical pharmacology development…
Certara2023 年 10 月 4 日
Certara Launches CoAuthor, a Regulatory and Medical Writing Tool
Using AI to gain efficiencies for medical writers PRINCETON, N. J.— 2023 年 10 月 3 日— Certara,…
Certara2023 年 10 月 3 日
Unlocking ROI through Omnichannel Stakeholder Engagement and Value Communication in Pharma
In a sector where both competition and stakeholder expectations are high, a comprehensive approach that…
Certara2023 年 10 月 2 日
Developing Pediatric PBPK Models for Differing Ethnic Populations
Physiologically-based pharmacokinetic (PBPK) modeling has proven invaluable in drug development, especially for pediatric populations, because…
Certara2023 年 9 月 29 日
What recent paediatric guidelines mean for drug developers
Justin Hay, Senior Director, Amy Cheung Senior Director of Integrated Drug Development, and Patrick Loebs…
Certara2023 年 9 月 25 日
